Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Camurus AB ( (SE:CAMX) ) has provided an update.
Camurus has announced the appointment of its Nomination Committee for the Annual General Meeting (AGM) 2026, consisting of representatives from major shareholders holding about 40% of the company’s shares and votes. This committee will present its proposals in the Notice to the AGM 2026, and shareholders are invited to submit their proposals by specified deadlines. The AGM is scheduled for 28 May 2026 in Lund, Sweden.
The most recent analyst rating on (SE:CAMX) stock is a Hold with a SEK684.00 price target. To see the full list of analyst forecasts on Camurus AB stock, see the SE:CAMX Stock Forecast page.
More about Camurus AB
Camurus is an international biopharmaceutical company focused on developing and commercializing innovative, long-acting medicines for severe and chronic diseases. Utilizing its proprietary FluidCrystal technology, Camurus has a robust R&D pipeline targeting dependence, pain, cancer, and endocrine diseases. The company operates in Europe, the US, and Australia, with headquarters in Lund, Sweden, and is listed on Nasdaq Stockholm under the ticker CAMX.
Average Trading Volume: 89,289
Technical Sentiment Signal: Hold
Current Market Cap: SEK37.38B
For a thorough assessment of CAMX stock, go to TipRanks’ Stock Analysis page.